It is a gastric proton pump inhibitor. Omeprazole is a
substituted benzimidazole derivative acting on the final step of
acid production & therefore controls intragastric acidity
irrespective of stimulus. It markedly inhibits basal and
stimulated gastric acid secretion. Thus it is antisecretory drug
which is very effective for rapidly healing peptic ulcers &
erosive oesophagitis & for reducing gastric acid hyper-secretion
in patients with Zollinger-Ellison syndrome.
The drug acts by relaxing blood vessels so that blood passes
through them more easily. This further helps to lower blood
Gastric ulcer: 20 mg once daily for 8 weeks in sever cases
increase to 0 40 mg once daily
Duodenal ulcer: 20 mg once daily for 4 weeks.
Zollinger Ellison Syndrome: 60 mg once daily.
Maintenance therapy: 20 0120 mg adjusted to response.
Contra- Indications: Hypersensitivity, neonates
The drug has certain side effects, that can affect individuals in
different ways. The following are some of the side effects, that
are often associated with the drug:
* Skin rash
Duodenal Ulcer (adults)
Prilosid is indicated for short-term treatment of active duodenal
ulcer in adults. Most patients heal within four weeks. Some
patients may require an additional four weeks of therapy.
Gastric Ulcer (adults)
Prilosid is indicated for short-term treatment (4-8 weeks) of
active benign gastric ulcer in adults.
Concomitant Gastric Malignancy
Symptomatic response to therapy with omeprazole does not preclude
the presence of gastric malignancy.
Atrophic gastritis has been noted occasionally in gastric corpus
biopsies from patients treated long-term with omeprazole.
Prilosid Delayed-Release Capsules are contraindicated in patients
with known hypersensitivity to any component of the formulation.
Clarithromycin is contraindicated in patients with a known
hypersensitivity to any macrolide antibiotic.
Concomitant administration of clarithromycin with cisapride,
pimozide, or terfenadine is contraindicated. There have been
post-marketing reports of drug interactions when clarithromycin
and/or erythromycin are co-administered with cisapride, pimozide,
or terfenadine resulting in cardiac arrhythmias (QT prolongation,
ventricular tachycardia, ventricular fibrillation, and torsades de
pointes) most likely due to inhibition of hepatic metabolism of
these drugs by erythromycin and clarithromycin. Fatalities have
been reported. (Please refer to full prescribing information for
clarithromycin before prescribing.)
Strip of 10 Capsules